ON 01910.Na: Polo-like kinase inhibitor oncolytic

Drugs of the Future

Volumn 36, Issue 6, 2011, Pages 433-440

  Taft, D R ^a   Dave, R ^a   Gillum, A M ^b   Maniar, M ^b  

^a LONG ISLAND UNIVERSITY   (United States)

^b Onconova Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ESTYBON; GEMCITABINE; IRINOTECAN; ON 01910; ORPHAN DRUG; OXALIPLATIN; POLO LIKE KINASE; RIGOSERTIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST ADENOCARCINOMA; CANCER INHIBITION; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DYSPNEA; DYSURIA; ENZYME INHIBITION; EPISTAXIS; FATIGUE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; HYPONATREMIA; LETHARGY; LEUKEMIA; LIVER CELL CARCINOMA; MAXIMUM TOLERATED DOSE; MITOSIS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PAIN; PANCREAS CARCINOMA; PNEUMONIA; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; URINARY TRACT INFECTION; VOMITING;

EID: 84952983201     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.06.1608923     Document Type: Review

References (44)

1. st ACS Natl Meet (March 27-31, Anaheim) 2011, Abst MEDI 106.
2. Reddy, M.V.R., Bell, S.C., Reddy, E.P. (Temple University; Onconova Therapeutics, Inc.). Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders. EP 1487428, JP 2005531503, WO 2003072062.
3. Reddy, E.P., Reddy, M.V.R., Bell, S.C. (Onconova Therapeutics, Inc.). Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders. US 7598232.
4. Degenhardt, Y., Lampkin, T. Targeting polo-like kinase in cancer therapy. Clin Cancer Res 2010, 16(2): 384-9.
5. Schoffski, P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009, 14(6): 559-70.
6. Chopra, P., Sethi, G., Dastidar, S.G., Ray, A. Polo-like kinase inhibitors: An emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs 2010, 19(1): 27-43.
7. Strebhardt, K. Multifaceted polo-like kinases: Drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010, 9(8): 643-60.
8. Weichert, W., Schmidt, M., Jacob, J. et al. Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology 2005, 5(2-3): 259-65. (Pubitemid 40754747)
9. Prasad, A., Park, I.W., Allen, H. et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene 2009, 28(12): 1518-28.
10. Gumireddy, K., Reddy, M.V.R., Cosenza, S.C. et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005, 7(3): 275-86. (Pubitemid 40568686)
11. Ma, X., Does, M., Raza, A., Mayne, S.T. Myelodysplastic syndromes: Incidence and survival in the United States. Cancer 2007, 109(8): 1536-42. (Pubitemid 46595689)
12. The Leukemia and Lymphoma Society. Facts 2010-2011. Available via http://www.lls.org/content/nationalcontent/resourcecenter/ freeeducationmaterials/generalcancer/pdf/facts . Accessed February 2, 2011.
13. Jiang, J., Li, Y., Wang, Y.L. et al. Anticancer effects of ON-1910Na. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 5382.
14. Preda, A., Ohnuma, T., Jiang, J., Holland, J.F., Reddy, E.P. Cross-resistance to ON01910.Na among drug-resistant human tumor cell lines. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 4707.
15. Jiang, J., Wang, Y.L., Li, Y., Reddy, E.P., Holland, J.F. Effects of ON1910Na in combination chemotherapy. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 9466.
16. Preda, A., Ohnuma, T., Reddy, E.P., Holland, J.F. Cytotoxic effect of ON 01910.Na in combination with ciplatin, flavopiridol, doxorubicin and other antitumor agents in vitro. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 5008.
17. Oussenko, I., Ohnuma, T., Jiang, J., Reddy, E.P., Holland, J. Combination of ON 01910.Na and oxaliplatin against DU-145 human prostate carcinoma and Bel7404 hepatoma cells in vitro. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst 654.
18. Jiang, J., Li, Y., Wang, Y.L., Qu, J., Mannam, P., Reddy, E.P., Holland, J. ON1910Na enhances the in vivo cancericidal effect of oxaliplatin. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 2271.
19. Oussenko, I., Holland, J.F., Reddy, E.P., Ohnuma, T. ON 01910.Na, a clinical stage anticancer mitotic inhibitor, produces prolonged hyperphosphorylation of RanGAP1•SUMO1 as a potential mechanism of G2/M arrest and apoptosis. Proc Am Assoc Cancer Res (AACR) 2010, 51: Abst 2500.
20. st Annu Meet Am Soc Hematol (Dec 5-8, New Orleans) 2009] 2009, 114(22): Abst 3827.
21. Jimeno, A., Wheelhouse, J., Chan, F. et al. A gene expression-based approach to devise combinations with gemcitabine (GEM) in pancreatic cancer (PC) identifies polo-like kinase 1 (Plk1) as a rational target. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst 1597.
22. th Annu Meet Am Soc Hematol (Dec 8-11, Atlanta) 2007] 2007, 110(11): Abst 822.
23. th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 1651.
24. Sloand, E.M., Olnes, M.J., Galili, N. et al. ON 01910.Na suppresses cyclin D1 accumulation in trisomy 8 myelodysplastic syndromes patients while decreasing bone marrow CD34+ blast counts and aneuploid clone size. Blood [51st Annu Meet Am Soc Hematol (Dec 5-8, New Orleans) 2009] 2009, 114(22): Abst 120.
25. st Annu Meet Am Soc Hematol (Dec 5-8, New Orleans) 2009] 2009, 114(22): Abst 412.
26. Chapman, C.M., Pérez-Galán, P., Wiestner, A. ON 01910.Na, a novel clinical grade PLK-1inhibitor, selectively induces apoptosis in human B cell chronic lymphocytic leukemia (B-CLL). Proc Am Assoc Cancer Res (AACR) 2009, 50: Abst 3654.
27. Pérez-Galán, P., Chapman, C., Sun, X., Gibellini, F., Liu, P., Raghavachari, N., Wiestner, A. ON 01910.Na, a clinical trial stage multi-kinase inhibitor, induces apoptosis in chronic lymphocytic leukemia (CLL) cells through inhibition of PI3K/AKT and activation of the JNK pathway resulting in NOXA and BIM upregulation. Proc Am Assoc Cancer Res (AACR) 2010, 51: Abst 3493.
28. Jimeno, A., Chan, A., Cusatis, G. et al. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene 2009, 28(4): 610-8.
29. Freshwater, R.E., Maniar, M., Taft, D.R. Cross-species pharmacokinetic comparison of a novel anticancer agent, ON.01910.Na. AAPS J [Annu Meet Am Soc Pharm Sci (AAPS) (Oct 29-Nov 2, San Antonio) 2006] 2006, 8(Suppl. 1): Abst W4356.
30. Chun, A.W., Cosenza, S.C., Taft, D.R., Maniar, M. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Cancer Chemother Pharmacol 2009, 65(1): 177-86.
31. Ohnuma, T., Preda, A., Reddy, E.P., Roboz, J., Holland, J.F. Influence of human serum albumin on cytotoxic activity Of ON01910.Na. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 4103.
32. Taft, D.R., Chun, A.W., Ren, C., Maniar, M. Proposed pathway of disposition of ON 01910.Na, a novel clinical trial stage anti-cancer agent: Implication of mrp2 in biliary excretion in the isolated perfused rat liver system. Proc Am Assoc Cancer Res (AACR) 2010, 51: Abst 3534.
33. Jimeno, A., Li, J., Messersmith, W.A. et al. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1pathway, in adult patients with solid tumors. J Clin Oncol 2008, 26(34): 5504-10.
34. Maniar, M., Mani, S., Ghalib, M. et al. Multicenter pharmacokinetic evaluation of ON 01910.Na, a novel broad-spectrum anticancer agent, in phase I single agent clinical trials in patients with solid tumors. Proc Am Assoc Cancer Res (AACR) 2010, 51: Abst 2766.
35. Skidan, I., Zinzar, S., Holland, J.F., Reddy, M.V.R., Reddy, E.P., Silverman, L.R. Toxicology of a novel small molecule ON 01910.Na on human bone marrow and leukemic cells in vitro. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 1310.
36. th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(15, Suppl.): Abst 2515.
37. Ohnuma, T., Cho, S.Y., Roboz, J. et al. Phase I study of ON 01910.Na by 3-day continuous infusion in patients with advanced cancer. J Clin Oncol 2006, 24: Abst 13137.
38. ClinicalTrials.gov: A Service of the U.S. National Institutes of Health. Available at http://clinicaltrials.gov/ct2/results?term=ON+01910. Accessed February 22, 2011.
39. nd Annu Meet Am Soc Hematol (Dec 7-10, Orlando) 2010] 2010, 116(21): Abst 2944.
40. st Annu Meet Am Soc Hematol (Dec 5-8, New Orleans) 2009] 2009, 114(22): Abst 3815.
41. th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 1659.
42. nd Annu Meet Am Soc Hematol (Dec 7-10, Orlando) 2010] 2010, 116(21): Abst 410.
43. nd Annu Meet Am Soc Hematol (Dec 7-10, Orlando) 2010] 2010, 116(21): Abst 3998.
44. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(18, Suppl.): Abst 13133.